New FAP-Index Tool Boosts Early Liver Disease Detection

Australian researchers have developed a new diagnostic tool, the Fibroblast Activation Protein (FAP)-Index, designed to detect serious liver disease earlier and more accurately. This innovative tool aims to improve the identification of individuals at risk of serious liver damage due to metabolic fatty liver disease.

Metabolic fatty liver disease is a prevalent and concerning condition. It often presents without early symptoms but can progress to liver scarring (fibrosis), cirrhosis, and ultimately, liver failure.

This condition affects an estimated one in three Australians, with projections indicating over 7 million cases by 2030, presenting a significant clinical challenge for identifying high-risk patients.

How the FAP-Index Works

The FAP-Index combines a blood test measuring Fibroblast Activation Protein (FAP) with routinely collected clinical information. This combination provides a more precise assessment of a patient's risk of liver scarring. FAP is a crucial biomarker, directly involved in the biological process that contributes to fibrosis, according to the study published in the Journal of Gastroenterology and Hepatology.

Enhanced Diagnostic Precision

The research team reported a significant improvement in diagnostic capabilities. Incorporating the FAP-Index with existing first-line blood test risk scores reduced uncertain results by up to 70 percent compared to using current screening tools alone.

This enhancement is intended to improve diagnostic precision and potentially reduce unnecessary specialist referrals and follow-up investigations.

Ziqi Vincent Wang, a PhD student at the Centenary Institute and the University of Sydney and the study's first author, highlighted the tool's practical benefits.

"The tool is designed to be simple, affordable, and practical for use in primary care settings."